Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein

被引:385
作者
Bogdanov, VY
Balasubramanian, V
Hathcock, J
Vele, O
Lieb, M
Nemerson, Y [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, Div Thrombosis Res, New York, NY 10029 USA
[2] CUNY Mt Sinai Sch Med, Cardiovasc Inst, New York, NY 10029 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nm841
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tissue factor (TF) is an essential enzyme activator that forms a catalytic complex with FVIIa and initiates coagulation by activating FIX and FX, ultimately resulting in thrombin formation(1). TF is found in adventitia of blood vessels(2) and the lipid core of atherosclerotic plaques(3). In unstable coronary syndromes, plaque rupture initiates coagulation by exposing TF to blood(4,5). Biologically active TF has been detected in vessel walls and circulating blood(6). Elevated intravascular TF has been reported in diverse pro-thrombotic syndromes such as myocardial infarction, sepsis, anti-phospholipid syndrome and sickle-cell disease(7-10). It is unclear how TF circulates, although it may be present in pro-coagulant microparticles(11,12). We now report identification of a form of human TF generated by alternative splicing. Our studies indicate that alternatively spliced human tissue factor (asHTF) contains most of the extracellular domain of TF but lacks a transmembrane domain and terminates with a unique peptide sequence. asHTF is soluble, circulates in blood, exhibits pro-coagulant activity when exposed to phospholipids, and is incorporated into thrombi. We propose that binding of asHTF to the edge of thrombi contributes to thrombus growth by creating a surface that both initiates and propagates coagulation.
引用
收藏
页码:458 / 462
页数:5
相关论文
共 25 条
[1]   Angiographic evolution of intracoronary thrombus and dissection following percutaneous transluminal coronary angioplasty (The Thrombolysis and Angioplasty in Unstable Angina [TAUSA] Trial) [J].
Ambrose, JA ;
Almeida, OD ;
Sharma, SK ;
Dangas, G ;
Ratner, DE ;
Torre, SR ;
Marmur, JD ;
Israel, DH ;
Cohen, M ;
LaForgia, S ;
Weiss, MB ;
HjemdahlMonsen, CE ;
Treulieb, N ;
Myler, RK ;
Shaw, R ;
Ward, K ;
Moses, J ;
Wilentz, J ;
Manikian, A ;
Undemir, C ;
Cohen, N ;
Unterecker, WJ ;
Ogilby, D ;
Hart, B ;
Grunwald, AM ;
Koss, J ;
Sauer, D ;
Garret, JS ;
Lagrotteria, J ;
Cowley, MJ ;
DeBottis, D ;
Anwar, A ;
Petrard, G ;
Sobolski, J ;
Barker, WM ;
Teoh, N ;
Sweeney, JM ;
Schuerr, D ;
Frederick, L ;
Wallenstein, S .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (05) :559-563
[2]   The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome [J].
Amengual, O ;
Atsumi, T ;
Khamashta, MA ;
Hughes, GRV .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) :276-281
[3]   INITIATION OF COAGULATION BY TISSUE FACTOR [J].
BACH, RR .
CRC CRITICAL REVIEWS IN BIOCHEMISTRY, 1988, 23 (04) :339-368
[4]   INFLUENCE OF ARTERIAL DAMAGE AND WALL SHEAR RATE ON PLATELET DEPOSITION - EXVIVO STUDY IN A SWINE MODEL [J].
BADIMON, L ;
BADIMON, JJ ;
GALVEZ, A ;
CHESEBRO, JH ;
FUSTER, V .
ARTERIOSCLEROSIS, 1986, 6 (03) :312-320
[5]  
BAUMGARTNER HR, 1980, J LAB CLIN MED, V95, P208
[6]  
Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639
[7]  
BERG HC, 1993, RANDOM WALKS BIOL, P37
[8]   MONOCLONAL-ANTIBODIES AGAINST THE C-TERMINAL PEPTIDE OF HUMAN TISSUE FACTOR FOR STUDIES OF THE CYTOPLASMIC DOMAIN [J].
CARSON, SD ;
YODER, SC .
BLOOD COAGULATION & FIBRINOLYSIS, 1992, 3 (06) :779-787
[9]   Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock [J].
Gando, S ;
Nanzaki, S ;
Sasaki, S ;
Aoi, K ;
Kemmotsu, O .
CRITICAL CARE MEDICINE, 1998, 26 (12) :2005-2009
[10]   Blood-borne tissue factor:: Another view of thrombosis [J].
Giesen, PLA ;
Rauch, U ;
Bohrmann, B ;
Kling, D ;
Roqué, M ;
Fallon, JT ;
Badimon, JJ ;
Himber, J ;
Riederer, MA ;
Nemerson, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (05) :2311-2315